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Summary
Agouti (ASIP) and Agouti-related protein (AgRP) are
endogenous antagonists of melanocortin receptors
that play critical roles in the regulation of pigmentation
and energy balance, respectively, and which arose
from a common ancestral gene early in vertebrate evo-
lution. The N-terminal domain of ASIP facilitates an-
tagonism by binding to an accessory receptor, but
here we show that the N-terminal domain of AgRP
has the opposite effect and acts as a prodomain that
negatively regulates antagonist function. Computa-
tional analysis reveals similar patterns of evolutionary
constraint in the ASIP and AgRP C-terminal domains,
but fundamental differences between the N-terminal
domains. These studies shed light on the relation-
ships between regulation of pigmentation and body
weight, and they illustrate how evolutionary structure
function analysis can reveal both unique and common
mechanisms of action for paralogous gene products.
Introduction
The Agouti-melanocortin system plays a critical role in
the regulation of pigmentation and energy balance in
a wide variety of vertebrate species. Agouti protein
(ASIP) and Agouti-related protein (AgRP) are para-
crine-signaling molecules; ASIP is normally produced
in the skin, where it promotes the synthesis of reddish-
yellow pigment by hair follicle melanocytes, while
AgRP is normally produced in the hypothalamus, where
it promotes increased feeding and decreased energy
expenditure. ASIP and AgRP act, respectively, via the
melanocortin 1 receptor (MC1R) expressed on melano-
cytes and the MC3R and MC4R expressed in the brain
to decrease receptor coupling to adenylate cyclase.
From a pharmacologic perspective, AgRP and ASIP
are inverse agonists, preventing receptor activation by
small melanocortin peptides such as a-melanocyte-
*Correspondence: gbarsh@stanford.edu (G.S.B.), glennm@
chemistry.ucsc.edu (G.L.M.)stimulating hormone (a-MSH) and, in addition, decreas-
ing basal receptor activity in the absence of a-MSH.
Orthologs of ASIP, AgRP, MC1R, and MC4R have
been identified in mammalian, teleost fish, and avian ge-
nomes, but not in invertebrate genomes, which sug-
gests that the Agouti-melanocortin system evolved by
gene duplication from individual ligand and receptor
genes in the last 500 million years. Indeed, the special-
ized expression patterns of ASIP and AgRP, and their
ability to crossreact with the other’s receptor in vitro,
are consistent with the view that distinct physiologic
functions of ASIP and AgRP have arisen through so-
called ‘‘subfunctionalization,’’ such that the current ex-
pression pattern and function of each molecule repre-
sents a subset of an ancestral gene that existed early
in vertebrate evolution.
Biophysical and pharmacologic studies of ASIP and
AgRP are consistent with this view, at least with respect
to the C-terminal domains of the two proteins. ASIP and
AgRP are, respectively, 109 and 112 amino acids in
length (after signal peptide cleavage), and they have
40 and 46 residue C-terminal domains that, in cell cul-
ture, are sufficient for potent antagonist function at their
cognate melanocortin receptors [1, 2]. The C-terminal
domains of ASIP and AgRP have nearly identical spac-
ing of 10 key cysteine residues; homonuclear 1H Nuclear
Magnetic Resonance (NMR) and biophysical studies
demonstrate that the domains have very similar protein
folds with an unusual inhibitor cystine knot (ICK) motif
stabilized by 5 disulfide bonds.
By contrast, the N-terminal domains of ASIP and
AgRP, while similar in length and exon structure, exhibit
little primary sequence similarity, and their physiological
roles are less clear. In the case of ASIP, the N-terminal
domain is required for interaction with Attractin, a large
single-transmembrane-spanning domain protein that is
required for ASIP signaling in vivo, and is thought to
act as an accessory receptor for ASIP-mediated antag-
onism of MC1R. An analogous role has been suggested
for AgRP, whereby the N terminus would interact with
syndecan-3, a CNS-specific cell surface proteoglycan,
and facilitate the ability of AgRP to antagonize MC4R
function [3–5]. While this hypothesis was supported by
initial genetic studies [3], recent work by White and col-
leagues [6, 7] provides strong evidence that the biolog-
ically active form of AgRP is its C-terminal fragment,
AgRP(83–132), produced by the action of a proprotein
convertase (PC). This result is particularly surprising
given that the biologically active form of ASIP consists
of the full-length protein (after signal peptidase cleav-
age) [8], ASIP(23–131), and that the genes that encode
AgRP and ASIP exhibit the same size and exon struc-
ture, pointing to a single and conserved evolutionary
origin for the entire protein-coding region.
To gain further insight into the biochemistry and evo-
lution of the Agouti-melanocortin system, we have car-
ried out structural and pharmacologic studies on full-
length AgRP, and we evaluated these observations
from the perspective of a comparative genomic analysis
based on measuring local evolutionary rates of AgRP
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tions confirm that the N-terminal domain of AgRP acts
to suppress antagonist activity of the biologically active
C-terminal domain, and that it does so in a way that is
independent of C-terminal domain structure. Genomic
analysis further indicates that the N-terminal domains
of the two proteins exhibit distinct patterns of evolu-
tionary constraint, revealing functional divergence.
Taken together, our results suggest that the different
roles of the N-terminal domains of AgRP and ASIP—
a prodomain and a ligand for an accessory receptor, re-
spectively—reflect distinct physiologic functions ac-
quired after duplication of an ancestral melanocortin
antagonist early in vertebrate evolution. These observa-
tions highlight an interesting mechanism for evolution
of paralogous genes whereby subfunctionalization
due to complementary expression patterns occurs to-
gether with coding sequence changes in distinct struc-
tural modules, and they illustrate how bioinformatic
structure function analysis can reveal both unique and
common mechanisms of action for paralogous gene
products.
Results
Our previous structural studies of C-terminal AgRP and
C-terminal ASIP were based on synthetic peptides of
46 and 40 residues, respectively. However, the size of
full-length AgRP is too large for efficient chemical syn-
thesis; therefore, we used a bacterial expression system
based on the work of Rosenfeld et al. [9], in which Met
and Lys replace the first 5 amino acids (after signal se-
quence cleavage) to yield a 109 residue protein, MKd5-
AgRP (referred to in what follows as full-length AgRP),
with the following sequence, (the cysteine-rich C-termi-
nal domain is underlined):
24–50 MKAPMEGIRRPDQALLPELPGLGLRAP
51–80 LKKTTAEQAEEDLLQEAQALAEVLDLQDRE
81–110 PRSSRRCVRLHESCLGQQVPCCDPCATCYC
111–132 RFFNAFCYCRKLGTAMNPCSRT
15N uniformly labeled full-length AgRP was expressed
and purified as described in Experimental Procedures
by making use of a His tag, which was then removed by
enterokinase cleavage. Folding of native protein under
oxidizing conditions was monitored by reverse-phase
high-performance liquid chromatography (HPLC) and
mass spectrometry; after 4 hr of folding, we recovered
a single HPLC peak that eluted at an earlier retention
time than the fully reduced protein, and that showed
the expected loss of 10 Da corresponding to five disul-
fide bridges.
Agonist binding to melanocortin receptors leads to
the production of cAMP; AgRP functions to suppress
this activity at MC3R and MC4R. To evaluate the func-
tional consequences of AgRP’s N-terminal domain, we
examined the ability of full-length AgRP to inhibit NDP-
MSH (a potent analog of a-MSH) at MC4R. As shown
in Figure 1A, full-length AgRP causes a dose-dependent
rightward shift, consistent with competitive antagonism,
and a standard Schild analysis gives an inhibition con-
stant (Ki) of 3.6 nM. This value isw10-fold greater than
reported values for the C-terminal domain alone [2, 10](see the Supplemental Data available with this article on-
line), thus demonstrating significantly reduced antago-
nist function. To ensure that the reduced activity was
not due to misfolded protein, full-length AgRP was first
folded and then proteolyzed with Factor Xa, which nor-
mally cleaves after exposed Arg residues, thus liberating
AgRP(83–132). Cleavage was carried out at pH 5.0 to
avoid disulfide exchange. AgRP(83–132), prepared in
this manner, was then directly compared to full-length
AgRP and commercially available AgRP(86–132) under
identical conditions. Measurements performed in tripli-
cate at two protein concentrations are shown in Figure 1B.
Full-length AgRP, AgRP(83–132), and AgRP(86–132) were
evaluated for their ability to suppress a-MSH-stimulated
cAMP production. AgRP(83–132) exhibited equivalent
activity to AgRP(86–132) (Ki = 0.35 nM, see Supplemental
Data). However, full-length AgRP was significantly less
potent than the two forms of C-terminal AgRP, showing
significant inhibition only when its concentration was
10-fold greater than that of a-MSH. Binding displace-
ment studies with the radioligand 125I-NDP-MSH were
performed to compare the affinities of full-length and
C-terminal AgRP. IC50 values are 18.1 6 0.4 nM for full-
length AgRP and 1.6 6 0.2 nM for AgRP(86–132) at
MC4R. These data argue that the decrease in function
of the full-length protein, relative to its cleaved C-termi-
nal domain, arises from an approximate 10-fold reduc-
tion in affinity.
To directly compare the NMR structures of C-terminal
and full-length AgRP, we produced 15N-labeled
AgRP(83–132) by cleavage of folded, full-length AgRP
with Factor Xa (vide supra). Spin systems for the 15N-la-
beled C-terminal AgRP(83–132) were assigned by using
3D nuclear Overhauser spectroscopy-heteronuclear
single quantum coherence (NOESY-HSQC) and 3D total
correlation spectroscopy- heteronuclear single quan-
tum coherence (TOCSY-HSQC), and the 1H chemical
shifts were found to be equivalent to those previously
reported. 1H chemical shifts are well dispersed and ex-
hibit considerable variation from random coil values,
consistent with a folded domain (Figures 2A and 2B)
[11, 12]. (15N chemical shifts are also well dispersed;
see Supplemental Data). 3D NMR spectra were used
to assign the spin systems of the C-terminal domain res-
idues in full-length AgRP. Subtraction of the conforma-
tionally sensitive 1H chemical shift values of AgRP(83–
132) from the corresponding values of the C-terminal
domain within full-length AgRP reveal little variation
(Figure 2B; C-terminal 15N chemical shifts are also con-
sistent between full-length and AgRP(83–132).; see Sup-
plemental Data). Along with the observation of long-
range nuclear Overhauser enhancements (NOEs) that
identify AgRP’s b sheet [13] (Supplemental Data), these
data demonstrate that structural characteristics of the
C-terminal domain in AgRP are affected very little by
the presence of the N-terminal residues.
Display of the full-length AgRP HSQC arising from the
backbone NH groups shows that essentially all of the
well-dispersed peaks are due to residues in the C-termi-
nal domain; the N-terminal residues show little or no dis-
persion. Consequently, we were not able to obtain se-
quential assignment of the N-terminal residues below
position 83. The lack of chemical shift dispersion for
the N-terminal domain is consistent with a polypeptide
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1299Figure 1. Pharmacology of Full-Length MKd5-AgRP versus C-Terminal AgRP(83–132)
AgRP(83–132) is obtained by cleavage of the oxidatively folded full-length protein.
(A) Inhibition of NDP-MSH-stimulated cAMP generation at hMC4R by full-length AgRP, and corresponding Schild analysis, reveals competitive
antagonism with a dissociation constant (Ki) of 3.6 nM.
(B) Both full-length AgRP and AgRP(83–132) inhibit MC4R cAMP production (measured at antagonist concentrations of 0.01 mM and 0.1 mM)
stimulated by a-MSH, but AgRP(83–132) is substantially more potent and, to within experimental error, equivalent to AgRP(86–132) with a Ki of
0.36 nM.
(C) Displacement of the radioligand 125I-NDP-MSH from MC4R by full-length AgRP and C-terminal AgRP, giving respective IC50 values of
18.1 6 0.4 nM and 1.6 6 0.2 nM.
Error bars represent standard deviations determined from triplicate measurements.segment that lacks well-defined secondary or tertiary
structure [14].
Individual 1H linewidths from the HSQC spectrum are
narrower for the N-terminal domain (18 Hz) than for the
C-terminal domain (27 Hz), indicative of N-terminal flex-
ibility [15, 16]. To directly evaluate protein backbonedynamics, 15N[1H]-NOEs were recorded for full-length
AgRP (Figure 3) [17, 18]. Nearly all of the positive peaks
correspond to C-terminal residues, demonstrating that
the C-terminal residues are ordered with respect to
each other, and that they tumble in solution as a domain
unit with a rotational correlation time, tc, >>1 ns. Within
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(A) The measured 1H chemical shifts from AgRP(83–132), minus the consensus random coil chemical shifts. The significant variation is con-
sistent with a folded domain. Circles represent measured values; squares represent proline, which is not observable in the HSQC spectra. The
arrows show the locations of b strands adjacent to the RFF triplet (residues 111–113).
(B) The difference in chemical shifts, full-length minus C-terminal, for residues 83–132. Note that the vertical axis is expanded by a factor of
three compared to that in (A). The limited scatter demonstrates that the HSQC from residues 83–132 in full-length AgRP is essentially equiv-
alent to that of the isolated C-terminal domain, AgRP(83–132). The 2 residues that do show significant 1H chemical shift variations are Arg89
and His91, as indicated.the C-terminal domain, only the last 2 residues (Arg131
and Thr132) showed either weak or negative heteronu-
clear NOE peaks, and these follow the last Cys residue
[13]. In contrast, nearly all N-terminal residues give ei-
ther no observable NOE or a strong negative crosspeak
consistent with backbone flexibility and tc << 1 ns, in-
cluding residues 83–86, between the C-terminal side of
the putative PC cleavage site and the first ICK cysteine
(residue 87). These data demonstrate that the N-terminal
residues of full-length AgRP are flexible and highly
dynamic.
While the structure of the C-terminal domain of MKd5-
AgRP is mostly unaffected by the N-terminal segment,
Arg89 and His91 do show small, but significant (>0.03
ppm), 1H chemical shift differences (Figure 2B). Interest-
ingly, these residues lie in a key loop of the ICK domain
that docks directly to melanocortin receptors, and which
is critical for high-affinity binding [13, 19–21]. Taken to-
gether, these data suggest that increased antagonist
potency of C-terminal relative to full-length AgRP (Fig-
ure 1) is not caused by a change in protein folding, but
by the ability of the flexible N-terminal domain to hinder
accessibility to the C-terminal domain. Structural find-
ings are summarized in a model of full-length AgRP (Fig-
ure 4A), based on the previously determined C-terminal
domain structure [13], and an N-terminal domain that
was energy minimized without distance restraints.
From an evolutionary perspective, these data present
a paradox. The C-terminal domains of AgRP and ASIP
are almost interchangeable from a structural and bio-
chemical perspective (Figures 4B and 4C); however,
the N-terminal domain of ASIP is required for receptor
antagonism, whereas, as indicated above, the N-termi-
nal domain of AgRP apparently inhibits receptor antag-
onism. To further investigate the basis of this difference,
we used evolution structure function (ESF) analysis [22]
to measure and compare local evolutionary rates for
both proteins. This method uses statistically rigorousmultiple sequence alignments and phylogenetic trees
to reveal evolutionarily constrained regions, which cor-
respond to the structurally and functionally most impor-
tant regions of the proteins.
There are nine ASIP and eight AgRP orthologs anno-
tated in publicly available databases; we identified an
additional three ASIP orthologs (Zebrafish, Fugu, Tetrao-
don) and four AgRP orthologs (Goldfish, Zebrafish, Fugu,
Tetraodon) by sequence similarity searches. ESF con-
straint profiles for seven mammalian homologs of ASIP
and AgRP (human, dog, cow, pig, mouse, rat, and opos-
sum) reveal large regions of evolutionary constraint in the
C-terminal portion of both proteins that correspond to
the cysteine-rich domains (Figure 5, highlighted in red).
An additional evolutionarily constrained region is appar-
ent in the N-terminal portion of ASIP, but not AgRP (Fig-
ure 5, highlighted in blue), indicating that an N-terminal
domain of ASIP has evolved at a rate similar to that of
the C-terminal domain. Strong evolutionary constraint
of the ASIP N-terminal domain is not surprising given
the requirement for this domain—serving as a ligand
for the accessory receptor Attractin—that has previously
been demonstrated in vivo and in vitro. However, the rel-
ative lack of constraint observed for the AgRP N-terminal
domain indicates that its ability to function as a prodo-
main has few requirements in terms of protein sequence
or structure. This observation is consistent with the NMR
studies described above and suggests, additionally, that
the AgRP N-terminal domain does not serve as a ligand
for other receptors.
We extended the ESF analysis to include five addi-
tional homologs from nonmammalian vertebrates
(Chicken, Goldfish, Zebrafish, Fugu, and Tetraodon).
The resulting profiles are qualitatively similar to those
obtained for mammalian homologs (Figure 5), which
suggests that evolutionary constraint of the ASIP N-ter-
minal domain has an origin similar to that of ASIP and
AgRP themselves, early during vertebrate evolution.
Structure and Evolution of ASIP and AgRP
1301Figure 3. NMR Spectra of Full-Length AgRP
(A) [15N, 1H]-HSQC spectrum of full-length
MKd5-AgRP. Assigned peaks are from resi-
dues 83–132.
(B) 15N [1H]-NOE spectrum of full-length
MKd5-AgRP. Positive NOEs are red, and
negative NOEs are green. Almost all N-termi-
nal residues are either negative or unobserv-
able, demonstrating the flexibility of this
segment.Discussion
Several aspects of melanocortin receptor biology are
based on comparative analysis of paralogous genes.
In particular, recognition and characterization of the
AgRP-MC3R and -MC4R pathways was based on hy-potheses and/or DNA sequences that emerged from
studying the ASIP-MC1R pathway; the ability of ASIP
to antagonize the MC4R serves as the basis for the still
widespread use of animals that ubiquitously express
ASIP (as in the Ay or Avy mutations) as an obesity model.
Nonetheless, there is a fundamental difference between
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AgRP functions as a prodomain [6], while the N-terminal
domain of ASIP serves as a ligand for an accessory re-
ceptor [8, 23]. Our work provides both biophysical and
evolutionary insight into this difference.
Clues that full-length AgRP might represent a propro-
tein with reduced activity compared to a C-terminal frag-
ment were apparent from initial studies of recombinant
AgRP produced by insect cells [2]; shorter forms gener-
ally exhibited greater antagonist activity than longer
forms when tested on Xenopus melanophores. How-
ever, these [2, 23] and additional studies [1, 6, 9, 10,
24] are complicated by the use of heterogeneous mix-
tures of partially purified recombinant protein [2, 23],
and/or by comparing full-length AgRP and C-terminal
Figure 4. Structural Features of AgRP and How They Compare with
Those of ASIP
(A) Representation of full-length AgRP. The structure of the Cys-
rich C-terminal domain was determined previously by 1H NMR
(PDB code: 1HYK) and is preserved in the full-length protein. Pos-
itive 15N[1H]-NOEs from residues 87–130 (Figure 3B) show that this
domain tumbles with a correlation time (tc) greater than 1 ns, con-
sistent with a structured unit. By contrast, the N-terminal domain is
flexible and has a backbone tc << 1 ns. Cysteine residues involved
in disulfide bonds are yellow; residues in the RFF triplet, required
for high-affinity MCR interactions, are blue. Residues in the putative
proprotein convertase recognition site are red. Cleavage takes
place after Arg82. The demonstrated flexibility of this segment is
consistent with PC cleavage in vivo. CYANA calculations [32] pro-
duced a broad ensemble of possible N-terminal structures (500 to-
tal were calculated); for clarity, only 1 of the several lowest energy
structures is shown.
(B) The NMR structure of the C-terminal domain of ASIP.
(C) Structural alignment of ASIP with the corresponding domain of
AgRP [33].AgRP prepared and folded as separate polypeptides,
often from different sources. The current approach, in
which we first folded full-length AgRP and then released
its C-terminal domain by proteolysis under conditions
that quench any disulfide bond rearrangement, controls
for any differences in peptide origin or preparation and
therefore demonstrates unequivocally that the N-termi-
nal domain in full-length AgRP inhibits the potency of
the MCR-binding domain AgRP(83–132). The NMR ex-
periments reported here show that the entire N-terminal
domain of AgRP up through residue 86 is flexible and un-
structured and thus certainly susceptible to proteolytic
cleavage. The mechanism of N-terminal inhibition prior
to proteolysis is likely to involve changes in the local
environment of positively charged Arg89 and His91,
probably via a transient collapse of a negatively charged
segment of the N-terminal domain (residues 57–78)
against the C-terminal surface involved in MCR docking,
which, in turn, interferes with receptor binding. Thus,
a primary biological role of the AgRP N-terminal domain
is to negatively regulate its activity such that potent mel-
anocortin antagonism is uncovered only after proteo-
lytic processing.
This conclusion provides a new aspect to our under-
standing of melanocortin biology, in which the function
of AgRP and ASIP in energy balance and pigmentation,
respectively, represent not only different patterns of
gene expression, but also different biochemical mecha-
nisms mediated by paralogous N-terminal domains.
Several considerations suggest that both the regulatory
and the structural differences between AgRP and ASIP
reflect so-called ‘‘subfunctionalization,’’ in which dupli-
cated genes are preserved during evolution due to the
partitioning of different functions between the dupli-
cates [25, 26]. Both melanocortin receptors and their
antagonistic ligands must have arisen early during verte-
brate evolution, since orthologs of ASIP and AgRP, and
of MC1R and MC4R, are found within vertebrate, but not
protochordate, genomes. Function of the ASIP N-termi-
nal domain as a ligand for an accessory receptor is likely
to have a similar origin, since the patterns of evolution-
ary constraint among mammalian and vertebrate ortho-
logs are nearly identical.
Taken together, these data suggest a model in which
a single (antagonistic) ligand and its cognate receptor
originally served to control both pigmentation and en-
ergy balance in an ancestral vertebrate several hundred
million years ago, perhaps as a means to coordinately
regulate metabolic rate and body temperature by means
of radiant energy. For example, inhibition of CNS mela-
nocortin signaling in a modern poikilotherm would prob-
ably decrease thyroid and reproductive function, while
inhibition of pigment melanocortin signaling would
probably decrease the absorption of radiant energy,
causing a reduction of body temperature. Both the be-
havioral and the thermoregulatory responses would be
adaptive during starvation and could help to explain
the somewhat surprising connection between pigmen-
tation and energy balance observed today.
Significance
Agouti (ASIP) and Agouti-related protein (AgRP) func-
tion as ligands for melanocortin receptors that control
Structure and Evolution of ASIP and AgRP
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Relative evolutionary constraint for each group of indicated proteins was carried out as described in Experimental Procedures; the multiple
sequence alignments are indicated below each plot. Areas highlighted in blue and red indicate regions of high local constraint that correspond
to the N-terminal domain of ASIP or the C-terminal domains of both proteins, respectively. Accession numbers for ASIP orthologs (and their
species and source) are P42127 (human, UniProt), Q5UK76 (dog, UniProt), Q29414 (cow, UniProt), Q6ZYM3 (pig, UniProt), Q03288 (mouse,
UniProt), Q99JA2 (rat, Uniprot), ENSMODP00000003361 (opossum, Ensembl), ENSGALP00000034003 (chicken, Ensembl), and Q5CC35 (gold-
fish, Uniprot). Accession numbers for AgRP orthologs (and their species and source) are O00253 (human, UniProt), 73957497 (dog, GenBank),
P56413 (cow, Uniprot), Q9TU18 (pig, UniProt), P56473 (mouse, UniProt), 62665164 (rat, GenBank), ENSMODP00000007302 (opossum,
Ensembl), and ENSGALP00000003505 (chicken, Ensembl).
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MC4R), respectively, and diverged from a common an-
cestor early in vertebrate evolution. Our previouswork
demonstrated that the carboxy-terminal regions of
ASIP and AgRP, which bind directly to melanocortin
receptors, have nearly identical three-dimensional
structures. A major challenge in the field has been to
understand the biochemical and biophysical basis
for differences in ASIP and AgRP action. We demon-
strate that the amino-terminal region of AgRP acts as
a prodomain that both inhibits function and is easily
cleaved from the full-length protein, and we provide
a biophysical explanation as to the nature of the inhi-
bition. By contrast, the homologous region of ASIP
plays a completely different role, serving as a ligand
for an accessory receptor that is required for in vivo
activity. We interpret our findings in the context of mo-
lecular evolution, demonstrating that the carboxy-ter-
minal domains of both proteins have similar levels of
constraint while the amino-terminal domains differ
dramatically. These observations contradict the long-
held view that biochemical mechanisms of action for
ASIP and AgRP are identical, and they have direct im-
plications both for interpreting previous work [3] and
for current approaches to obesity drug development.
Experimental Procedures
Bacterial Expression, Purification, and Folding
of Full-Length AgRP
The MKd5-AgRP(25–132) cDNA was created from the AgRP(1–132)
plasmid in the bluescript vector with a pair of synthetic oligonucleo-
tides, ACTGTAAGCTCATATGAAAGCCCCCATGGAGGGC and CGC
TCTAGAACTAGTGGATCCTGTTGG, which encode a BAM-H1 and
NDE1 cleavage site and Met Lys residues on the N terminus, respec-
tively, and amplify AgRP(25–132). To include a Factor Xa or entero-
kinase-cleavable 10x His tag, the MKd5-AgRP cDNA was ligated
into either the Pet 16B or Pet 19a cloning vectors, respectively (Invi-
trogen, San Diego, CA). The expression vectors were used to trans-
form BL21 E. coli. Cells were grown to an optical density of 0.6 in LB
media with ampicilin at 37C and were then induced with 50 mM
IPTG. The cell pellet was collected by centrifugation and was sus-
pended in lysis buffer (20 mM Tris [pH 7.5], 500 mM NaCl, 0.1% Tri-
ton, 10% glycerol) and sonicated for 4 min. The suspension was
centrifuged at 15,000 3 g, and both the soluble and insoluble frac-
tions were tested for the presence of AgRP by using PAGE gels.
10xHis-MKd5-AgRP was found exclusively in inclusion bodies.
These inclusion bodies were solubilized in 6 M guanidine hydrochlo-
ride, 10 mM Tris, 1 mM DTT, and 15 mM imidazole, at pH 8.0. Pro-
teins were purified by using a Ni-NTA superflow column, were
washed with 50 mM imidazole, and were eluted with 500 mM imidaz-
ole, followed by reverse-phase HPLC on a C18 column. His tag
removal was carried out with recombinant enterokinase or Factor
Xa (Invitrogen) in a modified cleavage buffer consisting of 20 mM
MES, 50 mM NaCl, and 2 mM CaCl2, at pH 6.4 over a 4 hr period.
To fold MKd5-AgRP, 1 mg lyophilized material was dissolved in
100 ml DMSO, followed by the addition of 10 ml folding buffer, which
contained 2.5 M guanidine hydrochloride, 100 mM Tris, 0.2 mM ox-
idized glutathione, and 1 mM reduced glutathione, at pH 8.0. Folding
was usually complete after 2 hr. HPLC showed the disappearance of
the peak corresponding to the fully reduced protein, followed by the
gradual emergence of a single HPLC peak that eluted at an earlier
retention time than the reduced material. Mass spectrometry of
the HPLC peak corresponding to folded MKd5-AgRP showed the
expected loss of 10 Da relative to the fully reduced material, due
to the formation of five disulfides bridges.
cAMP Assays
cAMP assays (performed with the Amersham Pharmacia Biotech
cAMP assay kit TRK 432) and 125I-NDP-MSH displacements wereperformed as previously described [1, 27]. HEK293 cells stably
transfected with the human melanocortin receptor hMC4R were
used for these studies. All experiments were performed in triplicate,
and data were analyzed with Graphpad Prism (Graphpad Software,
San Diego, CA). AgRP(86–132) was purchased from Peptide Insti-
tute, Inc.
NMR Sample Preparation
The structure of C-terminal AgRP(87–132) was previously solved at
pH 5.0, which produces the greatest solubility (>1.0 mM) [13]. How-
ever, under these conditions, full-length AgRP exhibits linewidths
and T1 and T2 relaxation times inconsistent with monomeric protein,
suggesting that the protein exists as soluble oligomers. Screening
a wide variety of conditions (pH, temperature, salt, cosolvents) by
NMR revealed that the protein was monomeric only when small
amounts of organic solvent were added, specifically 4% acetonitrile
w/v and 3% DMSO w/v at 37C.
The NMR sample for all spectra acquired for full-length AgRP con-
tained w200 mM protein in 50 mM acetate-d5 buffer (pH 5.0) with
10% D2O, 4% w/v acetonitrile-d3, and 3% w/v DMSO-d6. NMR
spectra for the C-terminal domain of AgRP contained the same
buffer conditions as the full-length protein with 50 mM protein con-
centration. All solutions contained 0.005% sodium azide to inhibit
bacterial growth. All isotopically enriched reagents were purchased
from Cambridge Isotope Laboratories (Cambridge, MA).
NMR Spectroscopy
Spectra were obtained on Varian 600 MHz spectrometers, with and
without a cryoprobe. NMR data were acquired at 37C. Resonance
assignments were made by using the following spectra: 2D 15N-
HSQC, 3D 15N-(NOESY)-HSQC with 100 ms mixing time, and 15N-
(TOCSY)-HSQC with 80 ms mixing time. Spectra were acquired by
using spectral widths of w1 = 2200, w2 = 10000, and, when applica-
ble, w3 = 10000. All experiments used sensitivity enhanced gradient
coherence selection. Heteronuclear 15N[1H]-NOE experiments were
performed under the same conditions as those described above and
with a relaxation delay of 3.0 s and a 3.0 s proton saturation.
Structure Calculations
The model of full-length AgRP was made by using the distance re-
straints previously determined for the C-terminal domain [13]. The
N-terminal residues were left with no distance restraints. 500 CYANA
structures were calculated, and, of these, one of the lowest-energy
structures was selected for the model. All structure representations
were developed with the aid of MOLMOL [28].
Evolution Structure Function Analysis
Local evolutionary rates over ASIP and AgRP were estimated by first
generating a multiple sequence alignment with Probcons (http://
probcons.stanford.edu/) [29] and deriving a phylogenetic tree by us-
ing SEMPHY (http://compbio.cs.huji.ac.il/semphy/) [30], and then,
while holding the tree topology fixed, calculating substitutions per
site by using PROTPARS (http://evolution.genetics.washington.
edu/phylip.html) [31]. These single-site rate values were smoothed
by using sliding-windows weighted averaging: in each 17-position-
wide window, the relative weight was highest for the value at the
center position, and it decreased linearly on either side to the
edge of the window. The resulting value was assigned to the position
in the protein corresponding to the center of the window. The rate
values were then converted to relative constraint by normalizing to
a range between 0 and 1, and subtracting from 1.
Supplemental Data
Supplemental Data include AgRP(86–132)/MC4R pharmacological
data, analysis of 15N chemical shifts, HPLC retention times of
AgRP constructs, C-terminal NOEs from full-length AgRP consistent
with the b sheet observed in AgRP(87–132), and 15N chemical shifts
and are available at http://www.chembiol.com/cgi/content/full/
13/12/1297/DC1/.
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